Molecular Signatures of Esophageal Atresia
- Conditions
- Esophageal Atresia
- Interventions
- Procedure: Esophageal biopsy collection during anastomosis
- Registration Number
- NCT06073158
- Lead Sponsor
- University Hospital, Lille
- Brief Summary
Although several studies have revealed signaling pathways as well as genes potentially involved in the development of esophageal atresia (EA), our understanding of the pathophysiology of EA lags behind improvements in the surgical and clinical care of patients born with this anomaly. However, a causative genetic abnormality can be identified in less than 10% of patients, even using more recent next-generation sequencing techniques. As most cases of EA associated with tracheoesophageal fistula (TOF) are sporadic, and the familial recurrence rate is low (1%), this suggests that epigenetic and environmental factors also contribute to the disease. Further investigations are needed to better understand the mechanisms underlying EA. That information can come from the oesophageal biopsies that are collected in routine care and long-term storage at the hospital. However, the impact of the length of the storage is still unknown.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 20
- Anastomosis group :
Born with esophageal atresia Anastomosis performed in Lille hospital Parents consent
- Control group : Born with esophageal atresia
- Both groups :
Parents refusing to participate in the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Anastomosis group Esophageal biopsy collection during anastomosis Esophageal biopsies collected during the anastomosis for the patient with esophageal atresia
- Primary Outcome Measures
Name Time Method Comparison of the mRNA expression from esophageal biopsies between long and short term storage The biopsies will be collected during the first year of life Transcriptomic profiles will be generated by the identification of mRNA and miRNA expression by 3'RNA-seq and sRNA-seq technologies. Differential expression between long and short term storage will be performed.\[exploratory and untargeted analysis\]
Comparison of the metabolites identification from esophageal biopsies between long and short term storage The biopsies will be collected during the first year of life Metabolomic profiles will be generated (untargeted analysis that will include mnulmerous lipids, amino-acids, ...). Differential expression between long and short term storage will be performed. \[exploratory and untargeted analysis\]
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CHU Lille
🇫🇷Lille, France